S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

Jazz Pharmaceuticals News Headlines (NASDAQ:JAZZ)

$130.86
-3.96 (-2.94 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$130.15
Now: $130.86
$134.27
50-Day Range
$134.82
MA: $144.90
$152.74
52-Week Range
$116.52
Now: $130.86
$154.24
Volume555,283 shs
Average Volume474,489 shs
Market Capitalization$7.40 billion
P/E Ratio12.52
Dividend YieldN/A
Beta1.18

Headlines

Jazz Pharmaceuticals (NASDAQ JAZZ) News Headlines

Source:
DateHeadline
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Hold" from AnalystsJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 2:24 AM
Narcolepsy Market Competitive Situation and Trends by 2025 | Teva Pharmaceutical, Shire, Jazz PharmaceuticalsNarcolepsy Market Competitive Situation and Trends by 2025 | Teva Pharmaceutical, Shire, Jazz Pharmaceuticals
www.marketwatch.com - February 22 at 6:25 AM
Heres Why Avadel Pharmaceuticals Jumped Higher TodayHere's Why Avadel Pharmaceuticals Jumped Higher Today
www.fool.com - February 21 at 5:35 PM
What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?
www.nasdaq.com - February 21 at 12:35 PM
JAZZ Makes Notable Cross Below Critical Moving AverageJAZZ Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - February 20 at 7:48 PM
Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on TuesdayJazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 18 at 6:23 AM
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares RallyImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally
finance.yahoo.com - February 17 at 12:50 PM
Jazz Pharma: FDA Grants Priority Review For LurbinectedinJazz Pharma: FDA Grants Priority Review For Lurbinectedin
www.nasdaq.com - February 17 at 7:49 AM
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung CancerPharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
finance.yahoo.com - February 17 at 7:49 AM
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Sells $213,270.00 in StockJazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Sells $213,270.00 in Stock
www.americanbankingnews.com - February 14 at 7:37 PM
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020
finance.yahoo.com - February 11 at 7:18 PM
Highly Rated Jazz Pharmaceuticals Sees A Hike In Its Composite RatingHighly Rated Jazz Pharmaceuticals Sees A Hike In Its Composite Rating
finance.yahoo.com - February 11 at 2:17 PM
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Expected to Post Quarterly Sales of $563.53 MillionJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Expected to Post Quarterly Sales of $563.53 Million
www.americanbankingnews.com - February 11 at 6:28 AM
Zacks: Brokerages Anticipate Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Will Announce Earnings of $4.15 Per ShareZacks: Brokerages Anticipate Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Will Announce Earnings of $4.15 Per Share
www.americanbankingnews.com - February 9 at 2:40 AM
Sleep Wake Disorder- Know which Players Undershooting Market ExpectationsSleep Wake Disorder- Know which Players Undershooting Market Expectations
www.marketwatch.com - February 8 at 7:46 AM
Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for PrialtJazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt
www.bloomberg.com - February 6 at 10:19 PM
IBD 50 Stocks To Watch: Top Drugmaker Jazz Pharma Working On New BaseIBD 50 Stocks To Watch: Top Drugmaker Jazz Pharma Working On New Base
finance.yahoo.com - February 3 at 7:10 PM
First Week of JAZZ September 18th Options TradingFirst Week of JAZZ September 18th Options Trading
www.nasdaq.com - February 3 at 2:10 PM
Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns "Buy" Rating from SunTrust BanksJazz Pharmaceuticals (NASDAQ:JAZZ) Earns "Buy" Rating from SunTrust Banks
www.americanbankingnews.com - January 31 at 2:43 PM
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Hold" from BrokeragesJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 1:50 AM
Top Key Players in Narcolepsy Drugs Market (2020-26) Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire PlcTop Key Players in Narcolepsy Drugs Market (2020-26) Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc
www.marketwatch.com - January 29 at 7:25 AM
Jazz Pharma Files for FDA Approval of a New Narcolepsy DrugJazz Pharma Files for FDA Approval of a New Narcolepsy Drug
www.fool.com - January 22 at 9:47 PM
Jazz Pharma submits marketing application for JZP-258Jazz Pharma submits marketing application for JZP-258
seekingalpha.com - January 22 at 4:47 PM
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with NarcolepsyJazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
finance.yahoo.com - January 22 at 4:46 PM
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting PeriodPharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
finance.yahoo.com - January 22 at 2:59 AM
Jazz Pharmaceuticals sleep disorder drug approved by European CommissionJazz Pharmaceuticals sleep disorder drug approved by European Commission
www.bizjournals.com - January 21 at 4:58 PM
Jazzs (JAZZ) New Sleep Drug Sunosi Gets Approval in EuropeJazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
finance.yahoo.com - January 21 at 4:58 PM
BRIEF-Jazz Pharmaceuticals Receives EU Marketing Authorization For SunosiBRIEF-Jazz Pharmaceuticals Receives EU Marketing Authorization For Sunosi
www.msn.com - January 20 at 7:41 PM
Jazz Pharmas Sunosi OKd in EuropeJazz Pharma's Sunosi OK'd in Europe
seekingalpha.com - January 20 at 2:40 PM
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep ApneaJazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
finance.yahoo.com - January 20 at 2:40 PM
Plasminogen Activator Inhibitor 1, Pipeline...Plasminogen Activator Inhibitor 1, Pipeline...
www.benzinga.com - January 20 at 8:57 AM
Global Narcolepsy Drug Market 2020-Jazz Pharmaceuticals ,Teva Pharmaceutical,NovartisGlobal Narcolepsy Drug Market 2020-Jazz Pharmaceuticals ,Teva Pharmaceutical,Novartis
www.marketwatch.com - January 15 at 11:18 PM
Jazz Pharmaceuticals (JAZZ) Presents At 38th Annual J.P. Morgan Healthcare Conference - SlideshowJazz Pharmaceuticals (JAZZ) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 14 at 8:53 PM
Narcolepsy Drugs Market is on position to touch $5.3 Billion by 2026Narcolepsy Drugs Market is on position to touch $5.3 Billion by 2026
www.marketwatch.com - January 14 at 3:36 AM
How Did Jazz Pharmaceuticals (JAZZ) Compare Against Top Hedge Fund Stocks in 2019?How Did Jazz Pharmaceuticals (JAZZ) Compare Against Top Hedge Fund Stocks in 2019?
finance.yahoo.com - January 13 at 5:23 PM
Jazz Pharmaceuticals Sees Composite Rating Improve To 96Jazz Pharmaceuticals Sees Composite Rating Improve To 96
finance.yahoo.com - January 13 at 5:23 PM
Maintaining $140 FVE for Jazz Following Agreement With PharmaMar for Lurbinectedin in SCLCMaintaining $140 FVE for Jazz Following Agreement With PharmaMar for Lurbinectedin in SCLC
finance.yahoo.com - January 10 at 4:16 PM
PharmaMars (PHMMF) Management on Conference Call to Discuss Jazz Pharmaceuticals License Agreement for Lurbinectedin in the U.S. - TranscriptPharmaMar's (PHMMF) Management on Conference Call to Discuss Jazz Pharmaceuticals License Agreement for Lurbinectedin in the U.S. - Transcript
seekingalpha.com - January 9 at 3:48 PM
ADVANZ PHARMA Announces Changes to its Board of Directors and Completion of its Continuance to Western EuropeADVANZ PHARMA Announces Changes to its Board of Directors and Completion of its Continuance to Western Europe
www.prnewswire.com - January 8 at 8:54 PM
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare ConferenceJazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 4:43 PM
Do You Like Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At This P/E Ratio?Do You Like Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At This P/E Ratio?
finance.yahoo.com - January 2 at 3:58 PM
Enrollment underway in study of Jazz Pharmas JZP-458 in blood cancersEnrollment underway in study of Jazz Pharma's JZP-458 in blood cancers
seekingalpha.com - December 30 at 2:57 PM
Create a Value-Based Portfolio With These 4 Low P/CF StocksCreate a Value-Based Portfolio With These 4 Low P/CF Stocks
finance.yahoo.com - December 26 at 8:22 AM
Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - December 24 at 4:15 PM
Jazz (JAZZ) Hits 52-Week High, Can the Run Continue?Jazz (JAZZ) Hits 52-Week High, Can the Run Continue?
finance.yahoo.com - December 23 at 2:38 PM
Orphan Drugs Market Worth at a CAGR 11.5% by 2024 | AbbVie, Celgene Corporation, BiogenOrphan Drugs Market Worth at a CAGR 11.5% by 2024 | AbbVie, Celgene Corporation, Biogen
www.marketwatch.com - December 23 at 8:09 AM
BRIEF-PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement For Lurbinectedin In U.S.BRIEF-PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement For Lurbinectedin In U.S.
www.msn.com - December 19 at 10:50 PM
BRIEF-Pharmamar & Jazz Pharmaceuticals Sign Exclusive License Agreement For LurbinectedinBRIEF-Pharmamar & Jazz Pharmaceuticals Sign Exclusive License Agreement For Lurbinectedin
www.msn.com - December 19 at 10:50 PM
Jazz Pharma in-licenses lung cancer candidate from PharmaMarJazz Pharma in-licenses lung cancer candidate from PharmaMar
seekingalpha.com - December 19 at 12:49 PM
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
finance.yahoo.com - December 19 at 12:49 PM
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Profit Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel